Monopar Therapeutics (MNPR)
(Real Time Quote from BATS)
$40.60 USD
-1.15 (-2.75%)
Updated Aug 5, 2025 10:42 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Monopar Therapeutics Inc. has a market cap of $255.31M, which represents its share price of $41.75 multiplied by its outstanding shares number of 6.12M. As a small-cap company, MNPR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
MNPR 40.60 -1.15(-2.75%)
Will MNPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength
Other News for MNPR
Monopar Therapeutics initiated with bullish view at Cantor Fitzgerald
Monopar Therapeutics (MNPR) Coverage Initiated by Cantor Fitzgerald | MNPR Stock News
Monopar Therapeutics (MNPR) Coverage Initiated with Buy Rating and $60 Target | MNPR Stock News
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Monopar Therapeutics (MNPR) Receives "Buy" Rating from Chardan Capital | MNPR Stock News